021-51111890
购物车（）
sales@molnova.cn
PF-05212377
CAS No. 1226793-34-5
PF-05212377 ( SAM-760;PF 5212377 )
产品货号. M10869 CAS No. 1226793-34-5
PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称PF-05212377
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease.
-
产品描述PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease.Alzheimer Disease Phase 2 Clinical
-
同义词SAM-760;PF 5212377
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体5-HT Receptor
-
研究领域Neurological Disease
-
适应症Alzheimer Disease
化学信息
-
CAS Number1226793-34-5
-
分子量356.44
-
分子式C18H20N4O2S
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Fullerton T, et al. Alzheimers Res Ther. 2018 Apr 5;10(1):38.
2. Fullerton T, et al. Alzheimers Res Ther. 2018 Apr 5;10(1):38.
2. Fullerton T, et al. Alzheimers Res Ther. 2018 Apr 5;10(1):38.
产品手册
关联产品
-
Facinicline hydrochl...
Facinicline hydrochloride is both a novel nicotinic alpha-7 receptor (alpha7nAChR) partial agonist (Ki = 6 nM) and an antagonist of 5-HT3(Ki = 1.2 nM).
-
Vabicaserin hydrochl...
Vabicaserin hydrochloride is a selective agonist of 5-hydroxytryptamine 2C (5-HT2C) receptor (EC50: 8 nM).
-
SEP-363856 hydrochlo...
SEP-363856 hydrochloride is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.
